Clinical Trial Update: Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA) [Phase 2]

View source ↗

Summary

A Phase 2 trial of alagebrium (SPECTRA) for hypertension has been terminated; this delivers a status update on the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Alagebrium (alagebrium)

Snippet

Sponsor: Synvista Therapeutics, Inc | Conditions: Hypertension | Phase 2 | Status: TERMINATED